Dongbao Biologics: Announcement of Resolutions of the Second Meeting of the 10th Board of Directors
Securities code: 300239 Securities abbreviation: Dongbao Biologics Announcement number: 2026-031
Bond code: 123214 Bond abbreviation: Dongho Convertible Bonds
Baotou Dongbao Biotechnology Co., Ltd.
Announcement of Resolutions of the Second Meeting of the Tenth Board of Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete and contains no false records, misleading statements or major omissions.
1. Convening of board of directors meetings
The second meeting of the 10th Board of Directors of Baotou Dongbao Biotechnology Co., Ltd. (hereinafter referred to as the "Company") was held at 15:30 on May 11, 2026 in the company conference room at No. 46 Huanghe Street, Baotou Rare Earth High-tech Zone. This meeting was convened and chaired by Mr. Wang Aiguo, chairman of the company. Notice of the meeting will be issued by phone, verbal or direct delivery on May 11, 2026. This meeting was held through on-site and communication voting. There were 5 directors who were supposed to participate in voting at this meeting, but 5 directors actually participated in voting at this meeting. Among them, 4 people attended by communication and 1 person attended on site. Director Mr. Wang Aiguo, Director Ms. Liu Yan, Independent Director Mr. Wang Jing, and Independent Director Mr. Erdun Tao Ketao attended the meeting via communication. Director Mr. Liu Fang attended the meeting on-site. The company's senior managers attended the meeting. The convening, holding and voting procedures of this meeting complied with the "Company Law of the People's Republic of China" and other laws, administrative regulations, departmental rules, normative documents, the "Articles of Association", the company's "Rules of Procedure for the Board of Directors" and other relevant provisions, and are legal and valid.
2. Review status of board of directors meeting
The "Proposal on Not Revising the Conversion Price of "Dongho Convertible Bonds" Downward" was reviewed and approved.
In view of the fact that the "Dongho Convertible Bonds" are still far away from the expiration of the duration, taking into account the company's basic situation, the overall stock price trend of the capital market, the market environment and many other factors, as well as the confidence in the company's long-term stable development, the "Dongho Convertible Bonds" conversion price will not be revised downward this time. At the same time, from the trading day after the board of directors' approval to November 11, 2026, if the conditions for downward revision of the "Dongho Convertible Bonds" conversion price are triggered again, no downward revision plan will be proposed. After this period (restarting from November 12, 2026), if the conditions for downward revision of the conversion price of "Dongho Convertible Bonds" are triggered again, the company's board of directors will convene another meeting to decide whether to exercise the right to downward revision of the conversion price of "Dongho Convertible Bonds".
Voting results: 5 votes in favor, 0 votes against, 0 abstentions.
This motion was passed by vote. For details, please refer to the "Announcement on Not Revising the Conversion Price of "Dongbao Convertible Bonds" Downward" disclosed by the company on cninfo.com on the same day.
3. Documents for reference
Resolution of the second meeting of the 10th Board of Directors;
Other documents required by Shenzhen Stock Exchange.
Announcement is hereby made.
Board of Directors of Baotou Dongbao Biotechnology Co., Ltd.
May 11, 2026